-
News | 2021.12.09
research, education, and economic development: first assessment of 3ia network actions
At the intersection of public and private research, the 3IA institutes create the ideal conditions for collaboration between world-class academic researchers and key drivers of innovation (start-ups, SMEs, or large corporations) and thereby strengthen the economic vitality of their environment. Although they each have their unique features, the 3IA insitutes also work in a network. Since...
-
News | 2021.09.21
Launch of the Medtech Generator & Accelerator program
The support project Medtech Generator & Accelerator (MGA), selected as a winning project in the second SIA call for proposals under the French government's Investing in the Future scheme (operated by Bpifrance), began in September 2021. Developed jointly by the Brain and Spine Institute, the Institut Imagine, the Institut Pasteur and the Institut de la Vision, the program aims to...
-
News | 2021.09.07
The Institut Pasteur attends the Cap’Carnot event on September 28, 2021
Cap'Carnot is the annual summer event organized by the Association of Carnot Institutes to promote dialog between the Carnot Institutes and drivers of innovation. For its second edition, Cap'Carnot will be held on Tuesday September 28, 2021 from 5 to 8pm at NEWCAP in Paris’ 15th arrondissement, and will be an opportunity to celebrate 15 years of R&D initiatives by Carnot...
-
News | 2021.03.04
Pfbioassays
The Institut Pasteur will be setting up the project Pfbioassays (in French) funded by the French government and the Greater Paris Region, on its campus (Thierry Rose and Sébastien Quesney). The aim of the project is to develop a highly automated technological bioassay system involving the packaging and analysis of serum samples. This new system, based on state-of-the-art...
-
News | 2022.06.14
A New Drug Target against Malaria
Malaria is a disease that continues to cause tremendous suffering and mortality in the tropics. This disease is caused by Plasmodium parasites. The species Plasmodium falciparum causes the severest and most deadly form of malaria. Scientists from Institut Pasteur studied the blood stage of the parasites and found a mechanism which could lead to new and efficient drugs against Malaria.Despite...
-
Document de presse | 2022.06.15
COVID-19: Identification of broadly SARS-CoV-2 neutralizing monoclonal antibodies
Although the different SARS-CoV-2 variants currently in circulation are undoubtedly less severe in vaccinated individuals in the general population, immunocompromised people are at greater risk of developing severe forms of COVID-19. Monoclonal antibodies currently offer the best approach, both as a preventive and curative treatment for these patients. Scientists from the Institut Pasteur and...
-
Article | 2022.06.20
4-year Research Group in entomology within Centre Pasteur Cameroun
To reinforce the research on arbovirus transmission at the Centre Pasteur du Cameroun (CPC), the Institut Pasteur will support the creation of a 4-year Research Group (G4) with a focus on entomology in this institute.
-
Document de presse | 2022.06.20
How to improve the care of childhood encephalitis in South-East Asia
Encephalitis is an acute inflammation of the brain tissue that affects children and adults, especially in South-East Asia. Researchers and physicians involved in the "South-East Asia encephalitis" (SEAe) project, coordinated by the Institut Pasteur in collaboration with the Pasteur Network, have demonstrated the importance of prevention as well as rapid and appropriate diagnosis and treatment of...
-
Article | 2022.06.20
4-year Research Group - Process
WHO CAN APPLY FOR A G4 PI POSITION?The G4 applicant should ideally be an early to mid-career post-doctoral scientist, wishing to establish a research group as an independent researcher. The proposed research project(s) should be innovative and timely yet realistic within the 4-year timeframe of the award. He/she should be able to conduct his/her research in an independent manner, initiate...
-
News | 2022.03.22
Shigella: GMP process for a vaccine candidate from the Institut Pasteur
Intravacc announces the publication of a GMP (Good Manufacturing Practices) process for a semi-synthetic Shigella glycoconjugate vaccine candidate developed at the Institut Pasteur (Paris).Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, announced the publication of a GMP (Good Manufacturing Practices) manufacturing and formulation...
